Conduit Pharmaceuticals and Charles River Laboratories have announced a partnership to evaluate AZD1656, a glucokinase activator, in a preclinical model of systemic lupus erythematosus (SLE).

As of Tuesday, February 18, vTv Therapeutics Inc.’s VTVT share price has dipped by 10.20%, which has investors questioning if this is right time to buy.

Glucokinase activation patterns the Ca 2+ wave axis, which originates from stochastic β-cell subpopulations on the islet periphery that change between oscillations. • The stochasticity of ‘leader’ ...

It is administered through oral route in the form of film coated tablet. It acts by targeting the glucokinase (GK). It is a new chemical entity. The drug candidate was under development for the ...

Glucokinase (also known as hexokinase IV, encoded by the GCK gene) enables phosphorylation of glucose, the rate-limiting step of glycolysis in the liver and pancreatic β cells (1). It plays a crucial ...

As compared to Type 1, Type 2 and other monogenic diabetes, GCK-MODY has unique characteristics reviewed in (18). The main feature observed in GCK-MODY patients is a mild fasting hyperglycemia, ...

Mammalian cardiomyocytes become post-mitotic shortly after birth. Understanding how this occurs is highly relevant to cardiac regenerative therapy. Yet, how cardiomyocytes achieve and maintain a ...